The invention discloses an application of Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy in preparation of medicaments for preventing and / or treating
enterovirus 71 infection. The invention confirms that the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has good antiviral effect in in-vitro
enterovirus 71 (EV 71) infection
cell tests. Meanwhile, the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxyhas certain killing effect on
enterovirus 71 (EV 71), can prevent enterovirus 71 (EV 71) infection, has good treating effect on enterovirus 71 (EV 71) infected cells, has good inhibition effect on
viral replication, and has more significant effect than a
positive control medicament of
ribavirin. In addition, the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has good inhibition effect on
inflammation responses caused by enterovirus 71 (EV 71), which reveals that the Lanosta-7,9(11),24-trien-3-one 15,26-dihydroxy has the prospect of being developed into anti-enterovirus 71 (EV 71) medicaments.